Titan Pharmaceuticals Company Profile (OTCMKTS:TTNP)

Analyst Ratings

Consensus Ratings for Titan Pharmaceuticals (OTCMKTS:TTNP) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.00

Analysts' Ratings History for Titan Pharmaceuticals (OTCMKTS:TTNP)
Show:
DateFirmActionRatingPrice TargetActions
5/29/2016Roth CapitalReiterated RatingBuy$7.75 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Titan Pharmaceuticals (OTCMKTS:TTNP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/11/2016        
5/10/2016Q116($0.12)($0.09)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.10)($0.11)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2015($0.02)($0.02)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015($0.03)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2015($0.01)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.02)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2014($0.02)($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/15/2013Q3 13($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Titan Pharmaceuticals (OTCMKTS:TTNP)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Titan Pharmaceuticals (OTCMKTS:TTNP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Titan Pharmaceuticals (OTCMKTS:TTNP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/19/2016Joseph A AkersDirectorBuy13,000$4.85$63,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/18/2016Sunil BhonsleCEOBuy10,000$4.96$49,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2016James R McnabDirectorBuy20,000$7.03$140,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/22/2016Sunil BhonsleCEOBuy11,763$3.56$41,876.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2016Sunil BhonsleCEOBuy5,841$2.72$15,887.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016James R McnabDirectorBuy16,363$3.16$51,707.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Marc RubinChairmanBuy5,000$3.25$16,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/11/2016Sunil BhonsleCEOBuy17,000$3.18$54,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/16/2015Sunil BhonslePresidentBuy10,000$0.70$7,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/28/2015Marc RubinChairmanBuy50,000$0.72$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Sunil BhonslePresidentBuy50,000$0.70$35,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Titan Pharmaceuticals (OTCMKTS:TTNP)
DateHeadline
07/22/16 09:52 AMThursday 7/21 Insider Buying Report: TTNP, MYCC
07/21/16 07:17 PMTitan Pharmaceuticals, Inc. (NASDAQ:TTNP)'s Company Shares Decreased 22.33% After High Volatility - Consumer Eagle
07/20/16 08:00 PMStock Moving Lower for the Month; Investor Update on Titan Pharmaceuticals Inc. (:TTNP) - Engelwood Daily
07/20/16 08:00 PMSunil Bhonsle Purchased 10000 Shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) - Consumer Eagle
07/20/16 08:00 PMTitan Pharmaceuticals, Inc. Can't Burn Your Long Portfolio. Has Another Strong Session - Press Telegraph
07/20/16 08:00 PMIncreased Stock Volatility Watch: Titan Pharmaceuticals Inc. (:TTNP) - Engelwood Daily
07/20/16 08:00 PMTitan Pharmaceuticals Inc Stock Technicals Hit Weakness - CML News
07/19/16 01:03 PMBraeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Nashville on July 22, 23 and 24 for Qualified Healthcare Providers - [PR Newswire] - NASHVILLE, Tenn., July 19, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that healthcare provider training and certification for Probuphine will take place on July 22, 23 and 24 in Nashville.
07/19/16 01:00 PMBraeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Honolulu on July 22 and 23 for Qualified Healthcare Providers - [PR Newswire] - HONOLULU, July 19, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that healthcare provider training and certification for Probuphine will take place on July 22 and 23 in Honolulu. Approved by ...
07/19/16 12:43 PMBraeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Oklahoma City on July 22, 23 and 24 for Qualified Healthcare Providers - [PR Newswire] - OKLAHOMA CITY, July 19, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that healthcare provider training and certification for Probuphine will take place on July 22, 23 and 24 in Oklahoma City.
07/19/16 12:42 PMBraeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Houston on July 22, 23 and 24 for Qualified Healthcare Providers - [PR Newswire] - HOUSTON, July 19, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that healthcare provider training and certification for Probuphine will take place on July 22, 23 and 24 in Houston. Approved ...
07/19/16 12:41 PMBraeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Seattle on July 22, 23 and 24 for Qualified Healthcare Providers - [PR Newswire] - SEATTLE, July 19, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that healthcare provider training and certification for Probuphine will take place on July 22, 23 and 24 in Seattle. Multiple ...
07/19/16 12:40 PMBraeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in San Diego on July 22, 23 and 24 for Qualified Healthcare Providers - [PR Newswire] - SAN DIEGO, July 19, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that healthcare provider training and certification for Probuphine will take place on July 22, 23 and 24 in San Diego. Multiple ...
07/19/16 12:01 PMBraeburn Pharmaceuticals to Conduct First Series of Probuphine® (buprenorphine) Implant Trainings in Jacksonville on July 22, 23 and 24 for Qualified Healthcare Providers - [PR Newswire] - JACKSONVILLE, Fla., July 19, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals announces that healthcare provider training and certification for Probuphine will take place on July 22, 23 and 24 in Jacksonville.
07/17/16 07:55 AMShares Moving Down on the Week: Titan Pharmaceuticals Inc. (:TTNP) - Engelwood Daily
07/15/16 05:54 PMTitan Pharmaceuticals, Inc. (TTNP) Current Analyst Ratings - Fiscal Standard
07/09/16 09:52 AMNew Broker Ratings For Titan Pharmaceuticals, Inc. (TTNP) - FTSE News
07/06/16 07:24 PMBroker Outlook For The Week Ahead Titan Pharmaceuticals, Inc. (TTNP) - Fiscal Standard
07/02/16 06:24 PMCompany Stock Lower on the Week Titan Pharmaceuticals Inc. (:TTNP) - Engelwood Daily
07/01/16 02:40 PMTITAN PHARMACEUTICALS INC Files SEC form 8-K, Other Events -
07/01/16 09:35 AMUpdate on Stock Volatility for: Titan Pharmaceuticals Inc. (:TTNP) - Engelwood Daily
06/30/16 08:42 AMShareholder Alert: Purcell Julie & Lefkowitz LLP Is Investigating Titan Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors - [PR Newswire] - NEW YORK, June 30, 2016 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim ...
06/29/16 09:38 AMStock Volatility in Review: Titan Pharmaceuticals Inc. (:TTNP) - Engelwood Daily
06/29/16 09:38 AMTitan Pharmaceuticals, Inc. (TTNP) Updated Price Targets - FTSE News
06/27/16 07:25 AMTitan Pharmaceuticals Added to Russell 3000 Index - MarketWatch
06/27/16 06:11 AMTitan Pharmaceuticals Added to Russell 3000 Index - [at noodls] - Press Releases SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/27/16 -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment ...
06/24/16 06:58 PMRecently Issued Stock Ratings For Titan Pharmaceuticals, Inc. (TTNP) - Fiscal Standard
06/20/16 06:29 PMTitan Pharmaceuticals Announces First Patients Treated With Probuphine® for Opioid Dependence
06/20/16 03:05 PMTITAN PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibi -
06/20/16 08:20 AMTitan Pharma (TTNP) Treats First Patients with Probuphine Implant - StreetInsider.com
06/20/16 08:20 AMThis Weeks Broker Views For Titan Pharmaceuticals, Inc. (TTNP) - Fiscal Standard
06/20/16 07:15 AMTitan Pharmaceuticals Announces First Patients Treated With Probuphine(R) for Opioid Dependence - [Marketwired] - Titan Pharmaceuticals, Inc. today announced that 10 patients received treatment last week with the Probuphine implant, making them the first patients in the United States to receive the medication since ...
06/16/16 10:13 AMTitan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine® for Opioid Dependence
06/16/16 08:30 AMProbuphine® (buprenorphine) Implant Phase 3 Data Presented at CPDD Annual Scientific Meeting - [PR Newswire] - PRINCETON, N.J. and PALM SPRINGS, Calif., June 16, 2016 /PRNewswire/ -- Braeburn Pharmaceuticals presented data yesterday from the poster of the Phase 3 study of Probuphine, a six-month subdermal buprenorphine ...
06/15/16 07:46 AMTitan Pharma (TTNP) Will Present Four Post-Hoc Analyses from Probuphine Phase 3 in Opioid Dependence - StreetInsider.com
06/15/16 06:19 AMTitan Pharmaceuticals Announces Rigorous Sensitivity Analyses Confirm Effectiveness of Probuphine(R) for Opioid Dependence - [at noodls] - Press Releases Poster on Analyses Presented at College of Problems of Drug Dependence 78th Annual Meeting PALM SPRINGS, CA -- (Marketwired) -- 06/15/16 -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today ...
06/13/16 09:53 AMTitan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine®
06/13/16 06:09 AMTitan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine(R) - [at noodls] - Press Releases More Than 800 Health Care Providers Already Certified Under the Probuphine REMS Program SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/13/16 -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ...
06/09/16 07:29 PMTitan Pharmaceuticals Inc. (NASDAQ:TTNP) Earnings Preview: Should Investors Be Nervous? - iStreetWire
06/07/16 07:12 PMSnapshot of Recent Traded Stocks: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Street Updates
06/04/16 06:59 PMAnalyst Recommended These Stocks for Investors: Titan Pharmaceuticals Inc. (NASDAQ:TTNP), Ascendis Pharma A/S ... - Beacon Chronicle
06/01/16 07:41 PMPrice Target Summary Report: Titan Pharmaceuticals Inc. (NASDAQ:TTNP), Hudson Pacific Properties, Inc. (NYSE:HPP) - Beacon Chronicle - Beacon ChroniclePrice Target Summary Report: Titan Pharmaceuticals Inc. (NASDAQ:TTNP), Hudson Pacific Properties, Inc. (NYSE:HPP)Beacon ChronicleTitan Pharmaceuticals Inc. (NASDAQ:TTNP) currently has High Price Target of $10. The Low and Mean Price Targets are $10 and $10 respectively. These price targets are a consensus analysis of 1 brokers. When having a look at Recommendation Trends of ...and more »
06/01/16 09:57 AMHealthcare Moving Stocks: Endo International plc (NASDAQ:ENDP) , Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) - Is stories - Is storiesHealthcare Moving Stocks: Endo International plc (NASDAQ:ENDP) , Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)Is storiesIn most recently trading session on 5/31/2016, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) climbed +2.48% while traded on 2.01 million shares versus it's an average volume of 455.74 thousand shares. The company recorded the last trade with the price of ...Endo International (NASDAQ:ENDP) moved up 1.05%: Titan (NASDAQ:TTNP), Flextronics International (NASDAQ ...Benchmark Monitorall 13 news articles »
05/31/16 07:22 PMTitan Pharmaceuticals, Inc. (TTNP) Director James R. Mcnab Purchases 20000 Shares - Let Me Know About This - Is storiesTitan Pharmaceuticals, Inc. (TTNP) Director James R. Mcnab Purchases 20000 SharesLet Me Know About ThisTitan Pharmaceuticals logo Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP) Director James R. Mcnab acquired 20,000 shares of the business's stock in a transaction on Tuesday, May 31st. The stock was acquired at an average cost of $7.03 per share, for a ...Analysts Update on Stocks: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Exelixis, Inc. (NASDAQ:EXEL)Street UpdatesObserving Healthcare Stocks Update: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Heat Biologics, Inc. (NASDAQ ...Is storiesTitan Pharmaceuticals, Inc. (NASDAQ:TTNP)'s director James Mcnab Made a Purchase of 20000 Shares of the CompanyHNNWsNews 4investorsall 5 news articles »
05/31/16 09:57 AMAnalyst Overview: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - Beacon Chronicle - Analyst Overview: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Ionis Pharmaceuticals Inc (NASDAQ:IONS)Beacon ChronicleLast Trade: The Company closed its last session at $6.86 Friday with the loss of -2.97%. The market capitalization of the company is $133.69 million, with the average Volume of $739,076.00. The stock currently has its 52-Week High range of $10.00 and ...and more »
05/31/16 09:57 AMWeekly Biotech Report Covering Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) FDA approval of probuphine - Market Exclusive - Market ExclusiveWeekly Biotech Report Covering Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) FDA approval of probuphineMarket ExclusiveThe situation with Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) developed similarly to what we predicted, so far. On May 27, the FDA approved Titan's Probuphine, an implant of buprenorphine for opiate addicts. In our previous report on Titan, we had said:.Analysts Update on Stocks: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Exelixis, Inc. (NASDAQ:EXEL)Street UpdatesObserving Healthcare Stocks Update: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) , Heat Biologics, Inc. (NASDAQ ...Is storiesall 5 news articles »
05/30/16 10:26 PMShire PLC (ADR) (NASDAQ:SHPG) & Titan Pharmaceuticals, (NASDAQ:TTNP) Healthcare Traders Recap - Wall Street 24 - Shire PLC (ADR) (NASDAQ:SHPG) & Titan Pharmaceuticals, (NASDAQ:TTNP) Healthcare Traders RecapWall Street 24Shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) declined -2.97% to $6.86. Braeburn Pharmaceuticals declares that the U.S. Food & Drug Administration (FDA) approved Probuphine, the first implant for the maintenance treatment of opioid dependence ...and more »
05/30/16 11:19 AMTitan Pharmaceuticals, Inc. (TTNP) Rating Reiterated by Roth Capital - Let Me Know About This - Titan Pharmaceuticals, Inc. (TTNP) Rating Reiterated by Roth CapitalLet Me Know About ThisTitan Pharmaceuticals logo Titan Pharmaceuticals, Inc. (OTCMKTS:TTNP)'s stock had its “buy” rating reiterated by equities researchers at Roth Capital in a report released on Sunday. Shares of Titan Pharmaceuticals (OTCMKTS:TTNP) opened at 6.86 on ...
05/30/16 11:19 AMHC Stocks Zone: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Ionis Pharmaceuticals Inc (NASDAQ:IONS) - share market updates (press release) - HC Stocks Zone: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Ionis Pharmaceuticals Inc (NASDAQ:IONS)share market updates (press release)Shares of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) ended Friday session in red amid volatile trading. The shares closed down -0.21 points or -2.97% at $6.86 with 9.43 million shares getting traded. Post opening the session at $8.51, the shares hit an ...and more »
05/28/16 09:40 AMTitan Pharmaceuticals, Inc. (TTNP) Bull Gap Sends Options Volume Soaring - Schaeffers Research (blog) - Schaeffers Research (blog)Titan Pharmaceuticals, Inc. (TTNP) Bull Gap Sends Options Volume SoaringSchaeffers Research (blog)It's been a big week for biotechs, and today is no exception. Drugmaker Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), for example, has jumped 13% to $8.02, after the Food and Drug Administration (FDA) approved its Probuphine implant -- the first of its ...Titan Pharmaceuticals Inc. (TTNP) Is Up Sharply After FDA ApprovalRTT NewsWhy Titan Pharmaceuticals Shares Are Rising24/7 Wall St.Healthcare Stock That is Just so Hot: Titan Pharmaceuticals, Inc. (NASDAQ:TTNP)The Point ReviewRisers & Fallers -iStreetWire -Franklin Independentall 12 news articles »

Social

About Titan Pharmaceuticals

Titan Pharmaceuticals, Inc. (Titan) is a specialty pharmaceutical company. The Company is engaged in developing therapeutics for the treatment of medical disorders. The Company's segment is engaged in the development of pharmaceutical products. The Company's product development programs utilize its long-term drug delivery platform, ProNeura. The Company's drug candidate, Probuphine, is being developed for the long-term maintenance treatment of opioid dependence. Titan's ProNeura continuous drug delivery system consists of a small, solid rod made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The Company focuses on developing two product development programs, the first one with a ropinirole implant for the treatment of Parkinson's disease (PD) and the second one with a Triiodothyronine (T3) implant for the treatment of hypothyroidism.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: TTNP
  • CUSIP:
Key Metrics:
  • Previous Close: $5.01
  • 50 Day Moving Average: $5.58
  • 200 Day Moving Average: $4.87
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $100.62M
  • Current Year EPS Consensus Estimate: $0.28 EPS
  • Next Year EPS Consensus Estimate: $-0.29 EPS
Additional Links:
Titan Pharmaceuticals (OTCMKTS:TTNP) Chart for Tuesday, July, 26, 2016